Viral vector (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Viral vector" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

2^nd place

2^nd place

18^th place

17^th place

7^th place

7^th place

2web.archive.org

1^st place

1^st place

49^th place

47^th place

doi.org

Pasin, Menzel & Daròs 2019, p. 1010. Pasin F, Menzel W, Daròs JA (2019). "Harnessed viruses in the age of metagenomics and synthetic biology: an update on infectious clone assembly and biotechnologies of plant viruses". Plant Biotechnology Journal. 17 (6): 1010–1026. doi:10.1111/pbi.13084. PMC 6523588. PMID 30677208.
Labbé, Vessillier & Rafiq 2021, p. 1. Labbé RP, Vessillier S, Rafiq QA (2021). "Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives". Viruses. 13 (152): 1528. doi:10.3390/v13081528. PMC 8402758. PMID 34452392.
Barth & Aylward 2024, p. 1. Barth ZK, Aylward FO (2024). "March of the proviruses". Proceedings of the National Academy of Sciences of the United States of America. 121 (14): e2402541121. Bibcode:2024PNAS..12102541B. doi:10.1073/pnas.2402541121. PMC 10998573. PMID 38527209.
Bulcha et al. 2021, pp. 1–2. Bulcha JT, Wang Y, Ma H, Tai PW, Gao G (2021). "Viral vector platforms within the gene therapy landscape". Signal Transduction and Targeted Therapy. 6 (1): 53. doi:10.1038/s41392-021-00487-6. PMC 7868676. PMID 33558455.
Nomaguchi et al. 2012, p. 1. Nomaguchi M, Fujita M, Miyazaki Y, Adachi A (2012). "Viral Tropism". Frontiers in Microbiology. 3 (281): 281. doi:10.3389/fmicb.2012.00281. PMC 3411105. PMID 22876241.
Moen et al. 2012, p. 2. Moen I, Jevne C, Wang J, Kalland K, Chekenya M, Akslen LA, et al. (2012). "Gene expression in tumor cells and stroma in dsRed 4T1 tumors in eGFP-expressing mice with and without enhanced oxygenation". BMC Cancer. 12 (21): 21. doi:10.1186/1471-2407-12-21. PMC 3274430. PMID 22251838.
Lanigan, Kopera & Saunders 2020, pp. 1, 7. Lanigan TM, Kopera HC, Saunders TL (2020). "Principles of Genetic Engineering". Genes. 11 (3): 603–618. doi:10.3390/genes11030291. PMC 7140808. PMID 32164255.
Sakuma, Barry & Ikeda 2012, p. 612. Sakuma T, Barry MA, Ikeda Y (2012). "Lentiviral vectors: basic to translational". Biochemical Journal. 443 (3): 603–618. doi:10.1042/BJ20120146. PMID 22507128.
Lanigan, Kopera & Saunders 2020, p. 1. Lanigan TM, Kopera HC, Saunders TL (2020). "Principles of Genetic Engineering". Genes. 11 (3): 603–618. doi:10.3390/genes11030291. PMC 7140808. PMID 32164255.
Bulcha et al. 2021, p. 1. Bulcha JT, Wang Y, Ma H, Tai PW, Gao G (2021). "Viral vector platforms within the gene therapy landscape". Signal Transduction and Targeted Therapy. 6 (1): 53. doi:10.1038/s41392-021-00487-6. PMC 7868676. PMID 33558455.
Pasin et al. 2024, p. 1. Pasin F, Uranga M, Charudattan R, Kwon CT (2024). "Engineering good viruses to improve crop performance". Nature Reviews Bioengineering: 1. doi:10.1038/s44222-024-00197-y.
Li et al. 2023, p. 2. Li X, Le Y, Zhang Z, Nian X, Liu B, Yang X (2023). "Viral Vector-Based Gene Therapy". International Journal of Molecular Sciences. 24 (9): 7736. doi:10.3390/ijms24097736. PMC 10177981. PMID 37175441.
Sasmita 2019, p. 29. Sasmita AO (2019). "Current viral-mediated gene transfer research for treatment of Alzheimer's disease". Biotechnology & Genetic Engineering Reviews. 35 (1): 26–45. doi:10.1080/02648725.2018.1523521. PMID 30317930.
Wang et al. 2023, p. 1. Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, et al. (2023). "Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases". Signal Transduction and Targeted Therapy. 8 (1): 149. doi:10.1038/s41392-023-01408-5. PMC 10081433. PMID 37029123.
Larocca & Schlom 2011, p. 1. Larocca C, Schlom J (2011). "Viral vector-based therapeutic cancer vaccines". The Cancer Journal. 17 (5): 359–371. doi:10.1097/PPO.0b013e3182325e63. PMC 3207353. PMID 21952287.
Elkashif et al. 2021, p. 1. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Ura, Okuda & Shimada 2014, p. 625. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Ura, Okuda & Shimada 2014, p. 624. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
McCann et al. 2022, p. 2. McCann N, O'Connor D, Lambe T, Pollard AJ (2022). "Viral vector vaccines". Current Opinion in Immunology. 77. doi:10.1016/j.coi.2022.102210. PMC 9612401. PMID 35643023.
Ura, Okuda & Shimada 2014, p. 624-625. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
McCann et al. 2022, p. 1. McCann N, O'Connor D, Lambe T, Pollard AJ (2022). "Viral vector vaccines". Current Opinion in Immunology. 77. doi:10.1016/j.coi.2022.102210. PMC 9612401. PMID 35643023.
McCann et al. 2022, pp. 1, 6–7. McCann N, O'Connor D, Lambe T, Pollard AJ (2022). "Viral vector vaccines". Current Opinion in Immunology. 77. doi:10.1016/j.coi.2022.102210. PMC 9612401. PMID 35643023.
Labbé, Vessillier & Rafiq 2021, p. 2. Labbé RP, Vessillier S, Rafiq QA (2021). "Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives". Viruses. 13 (152): 1528. doi:10.3390/v13081528. PMC 8402758. PMID 34452392.
Milone & O'Doherty 2018, pp. 1530–1531. Milone MC, O'Doherty U (2018). "Clinical use of lentiviral vectors". Leukemia. 32 (7): 1529–1541. doi:10.1038/s41375-018-0106-0. PMC 6035154. PMID 29654266.
Gruntman & Flotte 2018, pp. 1734. Gruntman AM, Flotte TR (2018). "The rapidly evolving state of gene therapy". The FASEB Journal. 32 (4): 1733–1740. doi:10.1096/fj.201700982R. PMID 31282760.
Gruntman & Flotte 2018, pp. 1733. Gruntman AM, Flotte TR (2018). "The rapidly evolving state of gene therapy". The FASEB Journal. 32 (4): 1733–1740. doi:10.1096/fj.201700982R. PMID 31282760.
Nemirov et al. 2023, p. 1. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Nemirov et al. 2023, pp. 1, 4. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Nemirov et al. 2023, pp. 1–2. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Nemirov et al. 2023, p. 4. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Nemirov et al. 2023, p. 7. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Li & Samulski 2020, p. 255. Li C, Samulski RJ (2020). "Engineering adeno-associated virus vectors for gene therapy". Nature Reviews Genetics. 21 (4): 255–272. doi:10.1038/s41576-019-0205-4. PMID 32042148.
Elkashif et al. 2021, p. 2. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Farhad et al. 2022, p. 2. Farhad T, Neves K, Arbuthnot P, Maepa MB (2022). "Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics". Genes. 13 (11): 1941. doi:10.3390/genes13111941. PMC 9689594. PMID 36360178.
Nemirov et al. 2023, pp. 3–4. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Ura, Okuda & Shimada 2014, p. 628. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Elkashif et al. 2021, p. 3. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Elkashif et al. 2021, pp. 3–4. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Elkashif et al. 2021, p. 8. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Ewer et al. 2017, p. 3020. Ewer K, Sebastian S, Spencer AJ, Gilbert S, Hill AV, Lambe T (2017). "Chimpanzee adenoviral vectors as vaccines for outbreak pathogens". Human Vaccines & Immunotherapeutics. 13 (12): 3020–3032. doi:10.1080/21645515.2017.1383575. PMC 5718829. PMID 29083948.
Elkashif et al. 2021, pp. 10, 11. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Haggerty et al. 2019, p. 69. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Haggerty et al. 2019, pp. 69–70. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Haggerty et al. 2019, p. 70. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Haggerty et al. 2019, pp. 71–74, 78. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Haggerty et al. 2019, p. 75. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Zhang et al. 2021, p. 1578. Zhang Z, Dong L, Zhao C, Zheng P, Zhang X, Xu J (2021). "Vaccinia virus-based vector against infectious diseases and tumors". Human Vaccines & Immunotherapeutics. 17 (6): 1578–1585. doi:10.1080/21645515.2020.1840887. PMC 8115763. PMID 33606578.
Ura, Okuda & Shimada 2014, p. 626. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Ura, Okuda & Shimada 2014, p. 627. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Kaynarcalidan, Mascaraque & Drexler 2021, p. 1. Kaynarcalidan O, Mascaraque SM, Drexler I (2021). "Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design". Biomedicines. 9 (11): 1780. doi:10.3390/biomedicines9121780. PMC 8698642. PMID 34944596.
Guo et al. 2019, p. 4. Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, et al. (2019). "Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics". Journal of Immunotherapy of Cancer. 9 (7): 6. doi:10.1186/s40425-018-0495-7. PMC 6325819. PMID 30626434.
Mody et al. 2020, p. 1. Mody PH, Pathak S, Hanson LK, Spencer JV (2020). "Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy". Virology. 11: 1178122X20913274. doi:10.1177/1178122X20913274. PMC 8142529. PMID 34093008.
Mody et al. 2020, pp. 3–4. Mody PH, Pathak S, Hanson LK, Spencer JV (2020). "Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy". Virology. 11: 1178122X20913274. doi:10.1177/1178122X20913274. PMC 8142529. PMID 34093008.
Mody et al. 2020, p. 4. Mody PH, Pathak S, Hanson LK, Spencer JV (2020). "Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy". Virology. 11: 1178122X20913274. doi:10.1177/1178122X20913274. PMC 8142529. PMID 34093008.
Khushalani et al. 2023, p. 1. Khushalani NI, Harrington KJ, Melcher A, Bommareddy PK, Zamarin D (2023). "Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment". Molecular Therapy Oncolytics. 31: 100729. doi:10.1016/j.omto.2023.100729. PMC 10570124. PMID 37841530.
Hromic-Jahjefendic & Lundstrom 2020, p. 631. Hromic-Jahjefendic A, Lundstrom K (2020). "Viral Vector-Based Melanoma Gene Therapy". Biomedicines. 8 (60): 60. doi:10.3390/biomedicines8030060. PMC 7148454. PMID 32187995.
Ura, Okuda & Shimada 2014, p. 631. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Sasso et al. 2020, p. 10. Sasso E, D'Alise AM, Zambrano N, Scarselli E, Folgori A, Nicosia A (2020). "New viral vectors for infectious diseases and cancer". Seminars in Immunology. 50. doi:10.1016/j.smim.2020.101430. PMID 33262065.
Schaefer et al. 2005, p. 1446. Schaefer A, Robbins KE, Nzilambi EN, Louis ME, Quinn TC, Folks TM, et al. (2005). "Divergent HIV and Simian Immunodeficiency Virus Surveillance, Zaire". Emerging Infectious Diseases. 11 (9): 1446–1448. doi:10.3201/eid1109.050179. PMC 3310624. PMID 16229778.
Pasin, Menzel & Daròs 2019, pp. 1010–1011. Pasin F, Menzel W, Daròs JA (2019). "Harnessed viruses in the age of metagenomics and synthetic biology: an update on infectious clone assembly and biotechnologies of plant viruses". Plant Biotechnology Journal. 17 (6): 1010–1026. doi:10.1111/pbi.13084. PMC 6523588. PMID 30677208.
Zaidi & Mansoor 2017, p. 1. Zaidi SS, Mansoor S (2017). "Viral Vectors for Plant Genome Engineering". Frontiers in Plant Science. 8: 539. doi:10.3389/fpls.2017.00539. PMC 5386974. PMID 28443125.
Petrov, Dymova & Richter 2022, p. 9. Petrov G, Dymova M, Richter V (2022). "Bacteriophage-Mediated Cancer Gene Therapy". International Journal of Molecular Sciences. 23 (14245): 14245. doi:10.3390/ijms232214245. PMC 9697857. PMID 36430720.
Pranjol & Hajitou 2015, p. 269. Pranjol ZI, Hajitou A (2015). "Bacteriophage-Mediated Cancer Gene Therapy". Viruses. 7 (1): 268–284. doi:10.3390/v7010268. PMC 4306838. PMID 25606974.
Petrov, Dymova & Richter 2022, p. 1. Petrov G, Dymova M, Richter V (2022). "Bacteriophage-Mediated Cancer Gene Therapy". International Journal of Molecular Sciences. 23 (14245): 14245. doi:10.3390/ijms232214245. PMC 9697857. PMID 36430720.
Elois et al. 2023, p. 1. Elois MA, Silva R, Pilati GV, Rodriguez-Lazaro D, Fongaro G (2023). "Bacteriophages as Biotechnological Tools". Viruses. 15 (2): 268–284. doi:10.3390/v15020349. PMC 9963553. PMID 36851563.
Abril et al. 2022, p. 11. Abril AG, Carrera M, Notario V, Sanchez-Perez A, Villa TG (2022). "The Use of Bacteriophages in Biotechnology and Recent Insights into Proteomics". Antibiotics. 11 (5): 653. doi:10.3390/antibiotics11050653. PMC 9137636. PMID 35625297.
Abril et al. 2022, p. 12. Abril AG, Carrera M, Notario V, Sanchez-Perez A, Villa TG (2022). "The Use of Bacteriophages in Biotechnology and Recent Insights into Proteomics". Antibiotics. 11 (5): 653. doi:10.3390/antibiotics11050653. PMC 9137636. PMID 35625297.
van der Loo & Wright 2016, p. 44. van der Loo J, Wright JF (2016). "Progress and challenges in viral vector manufacturing". Human Molecular Genetics. 25 (R1): R42-52. doi:10.1093/hmg/ddv451. PMC 4802372. PMID 26519140.
Merten et al. 2014, p. 184. Merten O, Schweizer M, Chahal P, Kamen AA (2014). "Manufacturing of viral vectors for gene therapy: part I. Upstream processing". Pharmaceutical Bioprocessing. 2 (2): 183–203. doi:10.4155/pbp.14.16.
van der Loo & Wright 2016, p. 45. van der Loo J, Wright JF (2016). "Progress and challenges in viral vector manufacturing". Human Molecular Genetics. 25 (R1): R42-52. doi:10.1093/hmg/ddv451. PMC 4802372. PMID 26519140.
Travieso et al. 2022, p. 1. Travieso T, Li J, Mahesh S, Mello JD, Blasi M (2022). "The use of viral vectors in vaccine development". npj Vaccines. 7 (1): 75. doi:10.1038/s41541-022-00503-y. PMC 9253346. PMID 35787629.
Lukiw 2023, p. 1. Lukiw WJ (2023). "Commentary: A tribute to Dr. Paul Berg (1926-2023) American biochemist, Nobel Laureate and discoverer of recombinant DNA technology, vaccine and genetic engineering". Frontiers in Cell and Developmental Biology. 11: 1210530. doi:10.3389/fcell.2023.1210530. PMC 10233203. PMID 37274735.
Jackson, Symons & Berg 1972, pp. 2904–2909. Jackson DA, Symons RH, Berg P (1972). "Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli". Proceedings of the National Academy of Sciences of the United States of America. 69 (10): 2904–2909. Bibcode:1972PNAS...69.2904J. doi:10.1073/pnas.69.10.2904. PMC 389671. PMID 4342968.
Lukiw 2023, p. 2. Lukiw WJ (2023). "Commentary: A tribute to Dr. Paul Berg (1926-2023) American biochemist, Nobel Laureate and discoverer of recombinant DNA technology, vaccine and genetic engineering". Frontiers in Cell and Developmental Biology. 11: 1210530. doi:10.3389/fcell.2023.1210530. PMC 10233203. PMID 37274735.
Moss 2013, p. 4220. Moss B (2013). "Reflections on the early development of poxvirus vectors". Vaccine. 31 (39): 4220–4222. doi:10.1016/j.vaccine.2013.03.042. PMC 3755097. PMID 23583893.
Wirth, Parker & Ylä-Herttuala 2013, p. 164. Wirth T, Parker N, Ylä-Herttuala S (2013). "History of gene therapy". Gene. 525 (2): 162–169. doi:10.1016/j.gene.2013.03.137. PMID 23618815.
Sheridan 2011, p. 121. Sheridan C (2011). "Gene therapy finds its niche". Nature Biotechnology. 29 (2): 121–128. doi:10.1038/nbt.1769. PMID 21301435.
Bezeljak 2022, pp. 2, 10. Bezeljak U (2022). "Cancer gene therapy goes viral: viral vector platforms come of age". Radiology and Oncology. 56 (1): 1–13. doi:10.2478/raon-2022-0002. PMC 8884858. PMID 35148469.
Wirth, Parker & Ylä-Herttuala 2013, p. 165. Wirth T, Parker N, Ylä-Herttuala S (2013). "History of gene therapy". Gene. 525 (2): 162–169. doi:10.1016/j.gene.2013.03.137. PMID 23618815.
Bezeljak 2022, p. 23. Bezeljak U (2022). "Cancer gene therapy goes viral: viral vector platforms come of age". Radiology and Oncology. 56 (1): 1–13. doi:10.2478/raon-2022-0002. PMC 8884858. PMID 35148469.
Wirth, Parker & Ylä-Herttuala 2013, pp. 166–167. Wirth T, Parker N, Ylä-Herttuala S (2013). "History of gene therapy". Gene. 525 (2): 162–169. doi:10.1016/j.gene.2013.03.137. PMID 23618815.
Bezeljak 2022, p. 2. Bezeljak U (2022). "Cancer gene therapy goes viral: viral vector platforms come of age". Radiology and Oncology. 56 (1): 1–13. doi:10.2478/raon-2022-0002. PMC 8884858. PMID 35148469.
Sánchez-Angulo 2023, pp. 1, 16. Sánchez-Angulo M (2023). "Microbial pathogens in the movies". FEMS Microbiology Letters. 370. doi:10.1093/femsle/fnad129. PMC 10754150. PMID 38059853.
Sánchez-Angulo 2023, p. 16. Sánchez-Angulo M (2023). "Microbial pathogens in the movies". FEMS Microbiology Letters. 370. doi:10.1093/femsle/fnad129. PMC 10754150. PMID 38059853.

harvard.edu

ui.adsabs.harvard.edu

Barth & Aylward 2024, p. 1. Barth ZK, Aylward FO (2024). "March of the proviruses". Proceedings of the National Academy of Sciences of the United States of America. 121 (14): e2402541121. Bibcode:2024PNAS..12102541B. doi:10.1073/pnas.2402541121. PMC 10998573. PMID 38527209.
Jackson, Symons & Berg 1972, pp. 2904–2909. Jackson DA, Symons RH, Berg P (1972). "Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli". Proceedings of the National Academy of Sciences of the United States of America. 69 (10): 2904–2909. Bibcode:1972PNAS...69.2904J. doi:10.1073/pnas.69.10.2904. PMC 389671. PMID 4342968.

nih.gov

pubmed.ncbi.nlm.nih.gov

Pasin, Menzel & Daròs 2019, p. 1010. Pasin F, Menzel W, Daròs JA (2019). "Harnessed viruses in the age of metagenomics and synthetic biology: an update on infectious clone assembly and biotechnologies of plant viruses". Plant Biotechnology Journal. 17 (6): 1010–1026. doi:10.1111/pbi.13084. PMC 6523588. PMID 30677208.
Labbé, Vessillier & Rafiq 2021, p. 1. Labbé RP, Vessillier S, Rafiq QA (2021). "Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives". Viruses. 13 (152): 1528. doi:10.3390/v13081528. PMC 8402758. PMID 34452392.
Barth & Aylward 2024, p. 1. Barth ZK, Aylward FO (2024). "March of the proviruses". Proceedings of the National Academy of Sciences of the United States of America. 121 (14): e2402541121. Bibcode:2024PNAS..12102541B. doi:10.1073/pnas.2402541121. PMC 10998573. PMID 38527209.
Bulcha et al. 2021, pp. 1–2. Bulcha JT, Wang Y, Ma H, Tai PW, Gao G (2021). "Viral vector platforms within the gene therapy landscape". Signal Transduction and Targeted Therapy. 6 (1): 53. doi:10.1038/s41392-021-00487-6. PMC 7868676. PMID 33558455.
Nomaguchi et al. 2012, p. 1. Nomaguchi M, Fujita M, Miyazaki Y, Adachi A (2012). "Viral Tropism". Frontiers in Microbiology. 3 (281): 281. doi:10.3389/fmicb.2012.00281. PMC 3411105. PMID 22876241.
Moen et al. 2012, p. 2. Moen I, Jevne C, Wang J, Kalland K, Chekenya M, Akslen LA, et al. (2012). "Gene expression in tumor cells and stroma in dsRed 4T1 tumors in eGFP-expressing mice with and without enhanced oxygenation". BMC Cancer. 12 (21): 21. doi:10.1186/1471-2407-12-21. PMC 3274430. PMID 22251838.
Lanigan, Kopera & Saunders 2020, pp. 1, 7. Lanigan TM, Kopera HC, Saunders TL (2020). "Principles of Genetic Engineering". Genes. 11 (3): 603–618. doi:10.3390/genes11030291. PMC 7140808. PMID 32164255.
Sakuma, Barry & Ikeda 2012, p. 612. Sakuma T, Barry MA, Ikeda Y (2012). "Lentiviral vectors: basic to translational". Biochemical Journal. 443 (3): 603–618. doi:10.1042/BJ20120146. PMID 22507128.
Lanigan, Kopera & Saunders 2020, p. 1. Lanigan TM, Kopera HC, Saunders TL (2020). "Principles of Genetic Engineering". Genes. 11 (3): 603–618. doi:10.3390/genes11030291. PMC 7140808. PMID 32164255.
Bulcha et al. 2021, p. 1. Bulcha JT, Wang Y, Ma H, Tai PW, Gao G (2021). "Viral vector platforms within the gene therapy landscape". Signal Transduction and Targeted Therapy. 6 (1): 53. doi:10.1038/s41392-021-00487-6. PMC 7868676. PMID 33558455.
Li et al. 2023, p. 2. Li X, Le Y, Zhang Z, Nian X, Liu B, Yang X (2023). "Viral Vector-Based Gene Therapy". International Journal of Molecular Sciences. 24 (9): 7736. doi:10.3390/ijms24097736. PMC 10177981. PMID 37175441.
Sasmita 2019, p. 29. Sasmita AO (2019). "Current viral-mediated gene transfer research for treatment of Alzheimer's disease". Biotechnology & Genetic Engineering Reviews. 35 (1): 26–45. doi:10.1080/02648725.2018.1523521. PMID 30317930.
Wang et al. 2023, p. 1. Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, et al. (2023). "Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases". Signal Transduction and Targeted Therapy. 8 (1): 149. doi:10.1038/s41392-023-01408-5. PMC 10081433. PMID 37029123.
Larocca & Schlom 2011, p. 1. Larocca C, Schlom J (2011). "Viral vector-based therapeutic cancer vaccines". The Cancer Journal. 17 (5): 359–371. doi:10.1097/PPO.0b013e3182325e63. PMC 3207353. PMID 21952287.
Elkashif et al. 2021, p. 1. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Ura, Okuda & Shimada 2014, p. 625. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Ura, Okuda & Shimada 2014, p. 624. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
McCann et al. 2022, p. 2. McCann N, O'Connor D, Lambe T, Pollard AJ (2022). "Viral vector vaccines". Current Opinion in Immunology. 77. doi:10.1016/j.coi.2022.102210. PMC 9612401. PMID 35643023.
Ura, Okuda & Shimada 2014, p. 624-625. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
McCann et al. 2022, p. 1. McCann N, O'Connor D, Lambe T, Pollard AJ (2022). "Viral vector vaccines". Current Opinion in Immunology. 77. doi:10.1016/j.coi.2022.102210. PMC 9612401. PMID 35643023.
McCann et al. 2022, pp. 1, 6–7. McCann N, O'Connor D, Lambe T, Pollard AJ (2022). "Viral vector vaccines". Current Opinion in Immunology. 77. doi:10.1016/j.coi.2022.102210. PMC 9612401. PMID 35643023.
Labbé, Vessillier & Rafiq 2021, p. 2. Labbé RP, Vessillier S, Rafiq QA (2021). "Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives". Viruses. 13 (152): 1528. doi:10.3390/v13081528. PMC 8402758. PMID 34452392.
Milone & O'Doherty 2018, pp. 1530–1531. Milone MC, O'Doherty U (2018). "Clinical use of lentiviral vectors". Leukemia. 32 (7): 1529–1541. doi:10.1038/s41375-018-0106-0. PMC 6035154. PMID 29654266.
Gruntman & Flotte 2018, pp. 1734. Gruntman AM, Flotte TR (2018). "The rapidly evolving state of gene therapy". The FASEB Journal. 32 (4): 1733–1740. doi:10.1096/fj.201700982R. PMID 31282760.
Gruntman & Flotte 2018, pp. 1733. Gruntman AM, Flotte TR (2018). "The rapidly evolving state of gene therapy". The FASEB Journal. 32 (4): 1733–1740. doi:10.1096/fj.201700982R. PMID 31282760.
Nemirov et al. 2023, p. 1. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Nemirov et al. 2023, pp. 1, 4. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Nemirov et al. 2023, pp. 1–2. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Nemirov et al. 2023, p. 4. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Nemirov et al. 2023, p. 7. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Li & Samulski 2020, p. 255. Li C, Samulski RJ (2020). "Engineering adeno-associated virus vectors for gene therapy". Nature Reviews Genetics. 21 (4): 255–272. doi:10.1038/s41576-019-0205-4. PMID 32042148.
Elkashif et al. 2021, p. 2. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Farhad et al. 2022, p. 2. Farhad T, Neves K, Arbuthnot P, Maepa MB (2022). "Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics". Genes. 13 (11): 1941. doi:10.3390/genes13111941. PMC 9689594. PMID 36360178.
Nemirov et al. 2023, pp. 3–4. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Ura, Okuda & Shimada 2014, p. 628. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Elkashif et al. 2021, p. 3. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Elkashif et al. 2021, pp. 3–4. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Elkashif et al. 2021, p. 8. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Ewer et al. 2017, p. 3020. Ewer K, Sebastian S, Spencer AJ, Gilbert S, Hill AV, Lambe T (2017). "Chimpanzee adenoviral vectors as vaccines for outbreak pathogens". Human Vaccines & Immunotherapeutics. 13 (12): 3020–3032. doi:10.1080/21645515.2017.1383575. PMC 5718829. PMID 29083948.
Elkashif et al. 2021, pp. 10, 11. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Haggerty et al. 2019, p. 69. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Haggerty et al. 2019, pp. 69–70. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Haggerty et al. 2019, p. 70. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Haggerty et al. 2019, pp. 71–74, 78. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Haggerty et al. 2019, p. 75. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Zhang et al. 2021, p. 1578. Zhang Z, Dong L, Zhao C, Zheng P, Zhang X, Xu J (2021). "Vaccinia virus-based vector against infectious diseases and tumors". Human Vaccines & Immunotherapeutics. 17 (6): 1578–1585. doi:10.1080/21645515.2020.1840887. PMC 8115763. PMID 33606578.
Ura, Okuda & Shimada 2014, p. 626. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Ura, Okuda & Shimada 2014, p. 627. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Kaynarcalidan, Mascaraque & Drexler 2021, p. 1. Kaynarcalidan O, Mascaraque SM, Drexler I (2021). "Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design". Biomedicines. 9 (11): 1780. doi:10.3390/biomedicines9121780. PMC 8698642. PMID 34944596.
Guo et al. 2019, p. 4. Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, et al. (2019). "Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics". Journal of Immunotherapy of Cancer. 9 (7): 6. doi:10.1186/s40425-018-0495-7. PMC 6325819. PMID 30626434.
Mody et al. 2020, p. 1. Mody PH, Pathak S, Hanson LK, Spencer JV (2020). "Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy". Virology. 11: 1178122X20913274. doi:10.1177/1178122X20913274. PMC 8142529. PMID 34093008.
Mody et al. 2020, pp. 3–4. Mody PH, Pathak S, Hanson LK, Spencer JV (2020). "Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy". Virology. 11: 1178122X20913274. doi:10.1177/1178122X20913274. PMC 8142529. PMID 34093008.
Mody et al. 2020, p. 4. Mody PH, Pathak S, Hanson LK, Spencer JV (2020). "Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy". Virology. 11: 1178122X20913274. doi:10.1177/1178122X20913274. PMC 8142529. PMID 34093008.
Khushalani et al. 2023, p. 1. Khushalani NI, Harrington KJ, Melcher A, Bommareddy PK, Zamarin D (2023). "Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment". Molecular Therapy Oncolytics. 31: 100729. doi:10.1016/j.omto.2023.100729. PMC 10570124. PMID 37841530.
Hromic-Jahjefendic & Lundstrom 2020, p. 631. Hromic-Jahjefendic A, Lundstrom K (2020). "Viral Vector-Based Melanoma Gene Therapy". Biomedicines. 8 (60): 60. doi:10.3390/biomedicines8030060. PMC 7148454. PMID 32187995.
Ura, Okuda & Shimada 2014, p. 631. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Sasso et al. 2020, p. 10. Sasso E, D'Alise AM, Zambrano N, Scarselli E, Folgori A, Nicosia A (2020). "New viral vectors for infectious diseases and cancer". Seminars in Immunology. 50. doi:10.1016/j.smim.2020.101430. PMID 33262065.
Schaefer et al. 2005, p. 1446. Schaefer A, Robbins KE, Nzilambi EN, Louis ME, Quinn TC, Folks TM, et al. (2005). "Divergent HIV and Simian Immunodeficiency Virus Surveillance, Zaire". Emerging Infectious Diseases. 11 (9): 1446–1448. doi:10.3201/eid1109.050179. PMC 3310624. PMID 16229778.
Pasin, Menzel & Daròs 2019, pp. 1010–1011. Pasin F, Menzel W, Daròs JA (2019). "Harnessed viruses in the age of metagenomics and synthetic biology: an update on infectious clone assembly and biotechnologies of plant viruses". Plant Biotechnology Journal. 17 (6): 1010–1026. doi:10.1111/pbi.13084. PMC 6523588. PMID 30677208.
Zaidi & Mansoor 2017, p. 1. Zaidi SS, Mansoor S (2017). "Viral Vectors for Plant Genome Engineering". Frontiers in Plant Science. 8: 539. doi:10.3389/fpls.2017.00539. PMC 5386974. PMID 28443125.
Petrov, Dymova & Richter 2022, p. 9. Petrov G, Dymova M, Richter V (2022). "Bacteriophage-Mediated Cancer Gene Therapy". International Journal of Molecular Sciences. 23 (14245): 14245. doi:10.3390/ijms232214245. PMC 9697857. PMID 36430720.
Pranjol & Hajitou 2015, p. 269. Pranjol ZI, Hajitou A (2015). "Bacteriophage-Mediated Cancer Gene Therapy". Viruses. 7 (1): 268–284. doi:10.3390/v7010268. PMC 4306838. PMID 25606974.
Petrov, Dymova & Richter 2022, p. 1. Petrov G, Dymova M, Richter V (2022). "Bacteriophage-Mediated Cancer Gene Therapy". International Journal of Molecular Sciences. 23 (14245): 14245. doi:10.3390/ijms232214245. PMC 9697857. PMID 36430720.
Elois et al. 2023, p. 1. Elois MA, Silva R, Pilati GV, Rodriguez-Lazaro D, Fongaro G (2023). "Bacteriophages as Biotechnological Tools". Viruses. 15 (2): 268–284. doi:10.3390/v15020349. PMC 9963553. PMID 36851563.
Abril et al. 2022, p. 11. Abril AG, Carrera M, Notario V, Sanchez-Perez A, Villa TG (2022). "The Use of Bacteriophages in Biotechnology and Recent Insights into Proteomics". Antibiotics. 11 (5): 653. doi:10.3390/antibiotics11050653. PMC 9137636. PMID 35625297.
Abril et al. 2022, p. 12. Abril AG, Carrera M, Notario V, Sanchez-Perez A, Villa TG (2022). "The Use of Bacteriophages in Biotechnology and Recent Insights into Proteomics". Antibiotics. 11 (5): 653. doi:10.3390/antibiotics11050653. PMC 9137636. PMID 35625297.
van der Loo & Wright 2016, p. 44. van der Loo J, Wright JF (2016). "Progress and challenges in viral vector manufacturing". Human Molecular Genetics. 25 (R1): R42-52. doi:10.1093/hmg/ddv451. PMC 4802372. PMID 26519140.
van der Loo & Wright 2016, p. 45. van der Loo J, Wright JF (2016). "Progress and challenges in viral vector manufacturing". Human Molecular Genetics. 25 (R1): R42-52. doi:10.1093/hmg/ddv451. PMC 4802372. PMID 26519140.
Travieso et al. 2022, p. 1. Travieso T, Li J, Mahesh S, Mello JD, Blasi M (2022). "The use of viral vectors in vaccine development". npj Vaccines. 7 (1): 75. doi:10.1038/s41541-022-00503-y. PMC 9253346. PMID 35787629.
Lukiw 2023, p. 1. Lukiw WJ (2023). "Commentary: A tribute to Dr. Paul Berg (1926-2023) American biochemist, Nobel Laureate and discoverer of recombinant DNA technology, vaccine and genetic engineering". Frontiers in Cell and Developmental Biology. 11: 1210530. doi:10.3389/fcell.2023.1210530. PMC 10233203. PMID 37274735.
Jackson, Symons & Berg 1972, pp. 2904–2909. Jackson DA, Symons RH, Berg P (1972). "Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli". Proceedings of the National Academy of Sciences of the United States of America. 69 (10): 2904–2909. Bibcode:1972PNAS...69.2904J. doi:10.1073/pnas.69.10.2904. PMC 389671. PMID 4342968.
Lukiw 2023, p. 2. Lukiw WJ (2023). "Commentary: A tribute to Dr. Paul Berg (1926-2023) American biochemist, Nobel Laureate and discoverer of recombinant DNA technology, vaccine and genetic engineering". Frontiers in Cell and Developmental Biology. 11: 1210530. doi:10.3389/fcell.2023.1210530. PMC 10233203. PMID 37274735.
Moss 2013, p. 4220. Moss B (2013). "Reflections on the early development of poxvirus vectors". Vaccine. 31 (39): 4220–4222. doi:10.1016/j.vaccine.2013.03.042. PMC 3755097. PMID 23583893.
Wirth, Parker & Ylä-Herttuala 2013, p. 164. Wirth T, Parker N, Ylä-Herttuala S (2013). "History of gene therapy". Gene. 525 (2): 162–169. doi:10.1016/j.gene.2013.03.137. PMID 23618815.
Sheridan 2011, p. 121. Sheridan C (2011). "Gene therapy finds its niche". Nature Biotechnology. 29 (2): 121–128. doi:10.1038/nbt.1769. PMID 21301435.
Sibbald 2001, p. 1612. Sibbald B (2001). "Death but one unintended consequence of gene-therapy trial". CMAJ. 164 (11): 1612. PMC 81135. PMID 11402803.
Bezeljak 2022, pp. 2, 10. Bezeljak U (2022). "Cancer gene therapy goes viral: viral vector platforms come of age". Radiology and Oncology. 56 (1): 1–13. doi:10.2478/raon-2022-0002. PMC 8884858. PMID 35148469.
Wirth, Parker & Ylä-Herttuala 2013, p. 165. Wirth T, Parker N, Ylä-Herttuala S (2013). "History of gene therapy". Gene. 525 (2): 162–169. doi:10.1016/j.gene.2013.03.137. PMID 23618815.
Bezeljak 2022, p. 23. Bezeljak U (2022). "Cancer gene therapy goes viral: viral vector platforms come of age". Radiology and Oncology. 56 (1): 1–13. doi:10.2478/raon-2022-0002. PMC 8884858. PMID 35148469.
Wirth, Parker & Ylä-Herttuala 2013, pp. 166–167. Wirth T, Parker N, Ylä-Herttuala S (2013). "History of gene therapy". Gene. 525 (2): 162–169. doi:10.1016/j.gene.2013.03.137. PMID 23618815.
Bezeljak 2022, p. 2. Bezeljak U (2022). "Cancer gene therapy goes viral: viral vector platforms come of age". Radiology and Oncology. 56 (1): 1–13. doi:10.2478/raon-2022-0002. PMC 8884858. PMID 35148469.
Sánchez-Angulo 2023, pp. 1, 16. Sánchez-Angulo M (2023). "Microbial pathogens in the movies". FEMS Microbiology Letters. 370. doi:10.1093/femsle/fnad129. PMC 10754150. PMID 38059853.
Feldman & Clayton 2022, pp. 2, 5. Feldman ZB, Clayton J (2022). "Genetics and Ethics in the "I am Legend" Corpus". Journal of Literature and Science. 14 (1–2): 94–107. PMC 9764423. PMID 36545402.
Sánchez-Angulo 2023, p. 16. Sánchez-Angulo M (2023). "Microbial pathogens in the movies". FEMS Microbiology Letters. 370. doi:10.1093/femsle/fnad129. PMC 10754150. PMID 38059853.

ncbi.nlm.nih.gov

Pasin, Menzel & Daròs 2019, p. 1010. Pasin F, Menzel W, Daròs JA (2019). "Harnessed viruses in the age of metagenomics and synthetic biology: an update on infectious clone assembly and biotechnologies of plant viruses". Plant Biotechnology Journal. 17 (6): 1010–1026. doi:10.1111/pbi.13084. PMC 6523588. PMID 30677208.
Labbé, Vessillier & Rafiq 2021, p. 1. Labbé RP, Vessillier S, Rafiq QA (2021). "Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives". Viruses. 13 (152): 1528. doi:10.3390/v13081528. PMC 8402758. PMID 34452392.
Bulcha et al. 2021, pp. 1–2. Bulcha JT, Wang Y, Ma H, Tai PW, Gao G (2021). "Viral vector platforms within the gene therapy landscape". Signal Transduction and Targeted Therapy. 6 (1): 53. doi:10.1038/s41392-021-00487-6. PMC 7868676. PMID 33558455.
Nomaguchi et al. 2012, p. 1. Nomaguchi M, Fujita M, Miyazaki Y, Adachi A (2012). "Viral Tropism". Frontiers in Microbiology. 3 (281): 281. doi:10.3389/fmicb.2012.00281. PMC 3411105. PMID 22876241.
Moen et al. 2012, p. 2. Moen I, Jevne C, Wang J, Kalland K, Chekenya M, Akslen LA, et al. (2012). "Gene expression in tumor cells and stroma in dsRed 4T1 tumors in eGFP-expressing mice with and without enhanced oxygenation". BMC Cancer. 12 (21): 21. doi:10.1186/1471-2407-12-21. PMC 3274430. PMID 22251838.
Lanigan, Kopera & Saunders 2020, pp. 1, 7. Lanigan TM, Kopera HC, Saunders TL (2020). "Principles of Genetic Engineering". Genes. 11 (3): 603–618. doi:10.3390/genes11030291. PMC 7140808. PMID 32164255.
Lanigan, Kopera & Saunders 2020, p. 1. Lanigan TM, Kopera HC, Saunders TL (2020). "Principles of Genetic Engineering". Genes. 11 (3): 603–618. doi:10.3390/genes11030291. PMC 7140808. PMID 32164255.
Bulcha et al. 2021, p. 1. Bulcha JT, Wang Y, Ma H, Tai PW, Gao G (2021). "Viral vector platforms within the gene therapy landscape". Signal Transduction and Targeted Therapy. 6 (1): 53. doi:10.1038/s41392-021-00487-6. PMC 7868676. PMID 33558455.
Li et al. 2023, p. 2. Li X, Le Y, Zhang Z, Nian X, Liu B, Yang X (2023). "Viral Vector-Based Gene Therapy". International Journal of Molecular Sciences. 24 (9): 7736. doi:10.3390/ijms24097736. PMC 10177981. PMID 37175441.
Wang et al. 2023, p. 1. Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, et al. (2023). "Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases". Signal Transduction and Targeted Therapy. 8 (1): 149. doi:10.1038/s41392-023-01408-5. PMC 10081433. PMID 37029123.
Larocca & Schlom 2011, p. 1. Larocca C, Schlom J (2011). "Viral vector-based therapeutic cancer vaccines". The Cancer Journal. 17 (5): 359–371. doi:10.1097/PPO.0b013e3182325e63. PMC 3207353. PMID 21952287.
Elkashif et al. 2021, p. 1. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Ura, Okuda & Shimada 2014, p. 625. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Ura, Okuda & Shimada 2014, p. 624. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
McCann et al. 2022, p. 2. McCann N, O'Connor D, Lambe T, Pollard AJ (2022). "Viral vector vaccines". Current Opinion in Immunology. 77. doi:10.1016/j.coi.2022.102210. PMC 9612401. PMID 35643023.
Ura, Okuda & Shimada 2014, p. 624-625. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
McCann et al. 2022, p. 1. McCann N, O'Connor D, Lambe T, Pollard AJ (2022). "Viral vector vaccines". Current Opinion in Immunology. 77. doi:10.1016/j.coi.2022.102210. PMC 9612401. PMID 35643023.
McCann et al. 2022, pp. 1, 6–7. McCann N, O'Connor D, Lambe T, Pollard AJ (2022). "Viral vector vaccines". Current Opinion in Immunology. 77. doi:10.1016/j.coi.2022.102210. PMC 9612401. PMID 35643023.
Labbé, Vessillier & Rafiq 2021, p. 2. Labbé RP, Vessillier S, Rafiq QA (2021). "Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives". Viruses. 13 (152): 1528. doi:10.3390/v13081528. PMC 8402758. PMID 34452392.
Milone & O'Doherty 2018, pp. 1530–1531. Milone MC, O'Doherty U (2018). "Clinical use of lentiviral vectors". Leukemia. 32 (7): 1529–1541. doi:10.1038/s41375-018-0106-0. PMC 6035154. PMID 29654266.
Nemirov et al. 2023, p. 1. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Nemirov et al. 2023, pp. 1, 4. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Nemirov et al. 2023, pp. 1–2. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Nemirov et al. 2023, p. 4. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Nemirov et al. 2023, p. 7. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Elkashif et al. 2021, p. 2. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Farhad et al. 2022, p. 2. Farhad T, Neves K, Arbuthnot P, Maepa MB (2022). "Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics". Genes. 13 (11): 1941. doi:10.3390/genes13111941. PMC 9689594. PMID 36360178.
Nemirov et al. 2023, pp. 3–4. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L (2023). "Lentiviral Vectors as a Vaccine Platform against Infectious Diseases". Pharmaceutics. 15 (3): 846. doi:10.3390/pharmaceutics15030846. PMC 10053212. PMID 36986707.
Ura, Okuda & Shimada 2014, p. 628. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Elkashif et al. 2021, p. 3. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Elkashif et al. 2021, pp. 3–4. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Elkashif et al. 2021, p. 8. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Ewer et al. 2017, p. 3020. Ewer K, Sebastian S, Spencer AJ, Gilbert S, Hill AV, Lambe T (2017). "Chimpanzee adenoviral vectors as vaccines for outbreak pathogens". Human Vaccines & Immunotherapeutics. 13 (12): 3020–3032. doi:10.1080/21645515.2017.1383575. PMC 5718829. PMID 29083948.
Elkashif et al. 2021, pp. 10, 11. Elkashif A, Alhashimi M, Sayedahmed EE, Sambhara S, Mittal SK (2021). "Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections". Clinical and Translational Immunology. 10 (10): e1345. doi:10.1002/cti2.1345. PMC 8510854. PMID 34667600.
Haggerty et al. 2019, p. 69. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Haggerty et al. 2019, pp. 69–70. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Haggerty et al. 2019, p. 70. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Haggerty et al. 2019, pp. 71–74, 78. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Haggerty et al. 2019, p. 75. Haggerty CL, Grecco GG, Reeves KC, Atwood B (2019). "Adeno-Associated Viral Vectors in Neuroscience Research". Molecular Therapy - Methods and Clinical Development. 17: 69–82. doi:10.1016/j.omtm.2019.11.012. PMC 6931098. PMID 31890742.
Zhang et al. 2021, p. 1578. Zhang Z, Dong L, Zhao C, Zheng P, Zhang X, Xu J (2021). "Vaccinia virus-based vector against infectious diseases and tumors". Human Vaccines & Immunotherapeutics. 17 (6): 1578–1585. doi:10.1080/21645515.2020.1840887. PMC 8115763. PMID 33606578.
Ura, Okuda & Shimada 2014, p. 626. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Ura, Okuda & Shimada 2014, p. 627. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Kaynarcalidan, Mascaraque & Drexler 2021, p. 1. Kaynarcalidan O, Mascaraque SM, Drexler I (2021). "Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design". Biomedicines. 9 (11): 1780. doi:10.3390/biomedicines9121780. PMC 8698642. PMID 34944596.
Guo et al. 2019, p. 4. Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, et al. (2019). "Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics". Journal of Immunotherapy of Cancer. 9 (7): 6. doi:10.1186/s40425-018-0495-7. PMC 6325819. PMID 30626434.
Mody et al. 2020, p. 1. Mody PH, Pathak S, Hanson LK, Spencer JV (2020). "Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy". Virology. 11: 1178122X20913274. doi:10.1177/1178122X20913274. PMC 8142529. PMID 34093008.
Mody et al. 2020, pp. 3–4. Mody PH, Pathak S, Hanson LK, Spencer JV (2020). "Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy". Virology. 11: 1178122X20913274. doi:10.1177/1178122X20913274. PMC 8142529. PMID 34093008.
Mody et al. 2020, p. 4. Mody PH, Pathak S, Hanson LK, Spencer JV (2020). "Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy". Virology. 11: 1178122X20913274. doi:10.1177/1178122X20913274. PMC 8142529. PMID 34093008.
Khushalani et al. 2023, p. 1. Khushalani NI, Harrington KJ, Melcher A, Bommareddy PK, Zamarin D (2023). "Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment". Molecular Therapy Oncolytics. 31: 100729. doi:10.1016/j.omto.2023.100729. PMC 10570124. PMID 37841530.
Hromic-Jahjefendic & Lundstrom 2020, p. 631. Hromic-Jahjefendic A, Lundstrom K (2020). "Viral Vector-Based Melanoma Gene Therapy". Biomedicines. 8 (60): 60. doi:10.3390/biomedicines8030060. PMC 7148454. PMID 32187995.
Ura, Okuda & Shimada 2014, p. 631. Ura T, Okuda K, Shimada M (2014). "Developments in Viral Vector-Based Vaccines". Vaccines. 2 (3): 624–641. doi:10.3390/vaccines2030624. PMC 4494222. PMID 26344749.
Schaefer et al. 2005, p. 1446. Schaefer A, Robbins KE, Nzilambi EN, Louis ME, Quinn TC, Folks TM, et al. (2005). "Divergent HIV and Simian Immunodeficiency Virus Surveillance, Zaire". Emerging Infectious Diseases. 11 (9): 1446–1448. doi:10.3201/eid1109.050179. PMC 3310624. PMID 16229778.
Pasin, Menzel & Daròs 2019, pp. 1010–1011. Pasin F, Menzel W, Daròs JA (2019). "Harnessed viruses in the age of metagenomics and synthetic biology: an update on infectious clone assembly and biotechnologies of plant viruses". Plant Biotechnology Journal. 17 (6): 1010–1026. doi:10.1111/pbi.13084. PMC 6523588. PMID 30677208.
Zaidi & Mansoor 2017, p. 1. Zaidi SS, Mansoor S (2017). "Viral Vectors for Plant Genome Engineering". Frontiers in Plant Science. 8: 539. doi:10.3389/fpls.2017.00539. PMC 5386974. PMID 28443125.
Petrov, Dymova & Richter 2022, p. 9. Petrov G, Dymova M, Richter V (2022). "Bacteriophage-Mediated Cancer Gene Therapy". International Journal of Molecular Sciences. 23 (14245): 14245. doi:10.3390/ijms232214245. PMC 9697857. PMID 36430720.
Pranjol & Hajitou 2015, p. 269. Pranjol ZI, Hajitou A (2015). "Bacteriophage-Mediated Cancer Gene Therapy". Viruses. 7 (1): 268–284. doi:10.3390/v7010268. PMC 4306838. PMID 25606974.
Petrov, Dymova & Richter 2022, p. 1. Petrov G, Dymova M, Richter V (2022). "Bacteriophage-Mediated Cancer Gene Therapy". International Journal of Molecular Sciences. 23 (14245): 14245. doi:10.3390/ijms232214245. PMC 9697857. PMID 36430720.
Elois et al. 2023, p. 1. Elois MA, Silva R, Pilati GV, Rodriguez-Lazaro D, Fongaro G (2023). "Bacteriophages as Biotechnological Tools". Viruses. 15 (2): 268–284. doi:10.3390/v15020349. PMC 9963553. PMID 36851563.
Abril et al. 2022, p. 11. Abril AG, Carrera M, Notario V, Sanchez-Perez A, Villa TG (2022). "The Use of Bacteriophages in Biotechnology and Recent Insights into Proteomics". Antibiotics. 11 (5): 653. doi:10.3390/antibiotics11050653. PMC 9137636. PMID 35625297.
Abril et al. 2022, p. 12. Abril AG, Carrera M, Notario V, Sanchez-Perez A, Villa TG (2022). "The Use of Bacteriophages in Biotechnology and Recent Insights into Proteomics". Antibiotics. 11 (5): 653. doi:10.3390/antibiotics11050653. PMC 9137636. PMID 35625297.
van der Loo & Wright 2016, p. 44. van der Loo J, Wright JF (2016). "Progress and challenges in viral vector manufacturing". Human Molecular Genetics. 25 (R1): R42-52. doi:10.1093/hmg/ddv451. PMC 4802372. PMID 26519140.
van der Loo & Wright 2016, p. 45. van der Loo J, Wright JF (2016). "Progress and challenges in viral vector manufacturing". Human Molecular Genetics. 25 (R1): R42-52. doi:10.1093/hmg/ddv451. PMC 4802372. PMID 26519140.
Travieso et al. 2022, p. 1. Travieso T, Li J, Mahesh S, Mello JD, Blasi M (2022). "The use of viral vectors in vaccine development". npj Vaccines. 7 (1): 75. doi:10.1038/s41541-022-00503-y. PMC 9253346. PMID 35787629.
Lukiw 2023, p. 1. Lukiw WJ (2023). "Commentary: A tribute to Dr. Paul Berg (1926-2023) American biochemist, Nobel Laureate and discoverer of recombinant DNA technology, vaccine and genetic engineering". Frontiers in Cell and Developmental Biology. 11: 1210530. doi:10.3389/fcell.2023.1210530. PMC 10233203. PMID 37274735.
Jackson, Symons & Berg 1972, pp. 2904–2909. Jackson DA, Symons RH, Berg P (1972). "Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli". Proceedings of the National Academy of Sciences of the United States of America. 69 (10): 2904–2909. Bibcode:1972PNAS...69.2904J. doi:10.1073/pnas.69.10.2904. PMC 389671. PMID 4342968.
Lukiw 2023, p. 2. Lukiw WJ (2023). "Commentary: A tribute to Dr. Paul Berg (1926-2023) American biochemist, Nobel Laureate and discoverer of recombinant DNA technology, vaccine and genetic engineering". Frontiers in Cell and Developmental Biology. 11: 1210530. doi:10.3389/fcell.2023.1210530. PMC 10233203. PMID 37274735.
Moss 2013, p. 4220. Moss B (2013). "Reflections on the early development of poxvirus vectors". Vaccine. 31 (39): 4220–4222. doi:10.1016/j.vaccine.2013.03.042. PMC 3755097. PMID 23583893.
Sibbald 2001, p. 1612. Sibbald B (2001). "Death but one unintended consequence of gene-therapy trial". CMAJ. 164 (11): 1612. PMC 81135. PMID 11402803.
Bezeljak 2022, pp. 2, 10. Bezeljak U (2022). "Cancer gene therapy goes viral: viral vector platforms come of age". Radiology and Oncology. 56 (1): 1–13. doi:10.2478/raon-2022-0002. PMC 8884858. PMID 35148469.
Bezeljak 2022, p. 23. Bezeljak U (2022). "Cancer gene therapy goes viral: viral vector platforms come of age". Radiology and Oncology. 56 (1): 1–13. doi:10.2478/raon-2022-0002. PMC 8884858. PMID 35148469.
Bezeljak 2022, p. 2. Bezeljak U (2022). "Cancer gene therapy goes viral: viral vector platforms come of age". Radiology and Oncology. 56 (1): 1–13. doi:10.2478/raon-2022-0002. PMC 8884858. PMID 35148469.
Sánchez-Angulo 2023, pp. 1, 16. Sánchez-Angulo M (2023). "Microbial pathogens in the movies". FEMS Microbiology Letters. 370. doi:10.1093/femsle/fnad129. PMC 10754150. PMID 38059853.
Feldman & Clayton 2022, pp. 2, 5. Feldman ZB, Clayton J (2022). "Genetics and Ethics in the "I am Legend" Corpus". Journal of Literature and Science. 14 (1–2): 94–107. PMC 9764423. PMID 36545402.
Sánchez-Angulo 2023, p. 16. Sánchez-Angulo M (2023). "Microbial pathogens in the movies". FEMS Microbiology Letters. 370. doi:10.1093/femsle/fnad129. PMC 10754150. PMID 38059853.

nytimes.com

Kolata 2017. Kolata G (27 November 2017). "Gene Therapy Hits a Peculiar Roadblock: A Virus Shortage". The New York Times. Archived from the original on 25 April 2023. Retrieved 20 May 2024.
Stolberg 1999. Stolberg SG (28 November 1999). "The Biotech Death of Jesse Gelsinger". The New York Times Magazine. Archived from the original on 25 October 2012. Retrieved 29 April 2024.

reuters.com

Reuters 2020. "Fact check: A vaccine did not turn characters in the movie 'I Am Legend' into zombies". Reuters. December 18, 2020. Retrieved 27 April 2024.

web.archive.org

Kolata 2017. Kolata G (27 November 2017). "Gene Therapy Hits a Peculiar Roadblock: A Virus Shortage". The New York Times. Archived from the original on 25 April 2023. Retrieved 20 May 2024.
Stolberg 1999. Stolberg SG (28 November 1999). "The Biotech Death of Jesse Gelsinger". The New York Times Magazine. Archived from the original on 25 October 2012. Retrieved 29 April 2024.